Analysts think DRRX stock price could increase by 792%
Jun 05, 2025, 11:25 AM
16.56%
What does DRRX do
DURECT, based in Cupertino, California, develops investigational therapies, including Larsucosterol for alcohol-associated hepatitis. Its FDA-approved products include POSIMIR and PERSERIS, while employing 48 staff since its 2000 IPO.
4 analysts think DRRX stock price will increase by 791.61%. The current median analyst target is $5.10 compared to a current stock price of $0.57. The lowest analysts target is $5.05 and the highest analyst target is $5.25.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
